Relationship between p53 status and radiosensitivity in human tumour cell lines

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 581-588

  Siles, E ^a   Villalobos, M ^a   Valenzuela, M T ^a   Nunez M I ^a   Gordon, A ^b   McMillan, T J ^b   Pedraza, V ^a   Ruiz De Almodovar J M ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cell cycle delay; Cellular radiosensitivity; G1 arrest; p53 response; Radiation

Indexed keywords

DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN INDUCTION; RADIOSENSITIVITY; TUMOR CELL LINE;

EID: 0030045087     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.101     Document Type: Article

References (40)

1. BAKER SJ, MARKOWITZ S, FEARON ER, WILLSON JKV AND VOGELSTEIN B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
2. BARTEK J, IGGO R, GANNON J AND LANE DP. (1990). Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5, 893-899.
3. BRACEY TS, MILLER JC, PREECE A AND PARASKEVA C. (1995). γ-Radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene, 10, 2391-2396.
4. CAILLEAU R, YOUNG R, OLIVE M AND REEVES Jr WJ. (1974). Breast tumour cell lines from pleural effusions. J Natl Cancer Inst., 53, 661-666.
5. 1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res., 54, 5054-5058.
6. COLLINS SJ, GALLO RC AND GALLAGHER RE. (1977). Continuous growth and differentiation of human myeloid cells in suspension culture. Nature, 270, 347-349.
7. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumour suppression. Cell, 75, 817-825.
8. FAN S, EL-DEIRY WS, BAE I, FREEMAN J, JONDLE D, BHATIA K, FORNACE Jr AJ, MAGRATH I, KOHN KW AND O'CONNOR P. (1994). p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830.
9. FRIEDMAN HS, BURGER PC, BIGNER SC, TROJANOWSKI J, HALPERIN EC AND BIGNER DD. (1985). Establishment and characterisation of the human medulloblastoma cell line and transplantable xenograft D283 MED. J. Neuropathol. Exp. Neurol., 44, 592-605.
10. HALL PA, RAY A, LEMOINE NR, MIDGLEY CA, KRAUSZT T AND LANE DP. (1991). p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet, 338, 513.
11. 1 cyclin-dependent kinases. Cell, 75, 805-816.
12. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
13. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B AND CRAIG RW. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
14. KASTAN MB, ZHAN Q, EL-DEIRY WS, CARRIER F, JACKS T, WALSH WV, PLUNKETT BS, VOGELSTEIN B AND FORNACE Jr AJ. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia-telangiectasia. Cell, 71, 587-597.
15. KEYDAR I, CHEN L, KARBY S, WEISS FR, DELAREA J, RADU M, CHAITIK S AND BRENNER HJ. (1979). Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer, 15, 659-670.
16. KUERBITZ SJ, PLUNKETT BS, WALSH WV AND KASTAN MB. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
17. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453-456.
18. LEVINE AJ, PERRY ME, CHANG A, SILVER A, DITTMER D, WU M AND WELSH D. (1994). The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer, 69, 409-416.
19. LIPPMAN M, BOLAN G AND HUFF K. (1976). The effects of estrogen and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36, 4595-4601.
20. LOWE SW, SCHMITT EM, SCHMITT SW, OSBORNE BA AND JACKS T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847-849.
21. LOWE SW, BODIS S, MCCLATCHEY A, REMINGTON L, RULEY HE, FISHER DE, HOUSEMAN DE AND JACKS T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
22. MCILWRATH AJ, VASEY PA, ROSS GM AND BROWN R. (1994). Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718-3722.
23. MASTERS JRW, HEPBURN PJ, WALKER L, HIGHMAN WJ, TREJDOSIEWICZ LK, POVEY S, HILL BT, RIDDLE PR AND FRANKS LM. (1986). Tissue culture models of transitional cell carcinoma: characterization of 22 human urothelial cell lines. Cancer Res., 4, 3630-3636.
24. MERRITT AJ, POTTEN CS, KEMP J, HICKMAN JA, BALMAIN A, LANE DP AND HALL PA (1994). The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res., 54, 614-617.
25. 2/M delay and cellular radiosensitivity. Int. J. Radiat. Biol., 66, 373-379.
26. NÚÑEZ MI, VILLALOBOS M, OLEA N, VALENZUELA MT, PEDRAZA V, MCMILLAN TJ AND RUIZ DE ALMODÓVAR JM. (1995). Radiation-induced DNA double-strand break rejoining in human tumour cells. Br. J. Cancer, 71, 311-316.
27. O'CONNOR PM, JACKMAN J, JONDLE D, BHATIA K, MAGRATH I AND KOHN K. (1993). Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53, 4776-4780.
28. POWELL SN AND MCMILLAN TJ. (1994). The repair fidelity of restriction enzyme-induced double strand breaks in plasmid DNA correlates with radioresistance in human tumor cell lines. Int. J. Rad. Oncol. Biol. Phys., 29, 1035-1040.
29. ROBINSON JP. (1993). Measurements of DNA. In Handbook of Flow Cytometry Methods, Robinson JP (ed.), Darzynkiewicz Z, Dean P, Dressier L, Tanke H and Wheeless L. (assoc eds) pp. 90-126. Wiley-Liss: New York.
30. RUIZ DE ALMODÓVAR JM, NÚÑEZ MI, MCMILLAN TJ, OLEA N, MORT C, VILLALOBOS M, PEDRAZA V AND STEEL GG. (1994). Initial DNA damage is a determinant of intrinsic cellular radiosensitivity. Br. J. Cancer, 69, 457-462.
31. SCHLICHTHOLZ B, LEGROS Y, GILLET D, GAILLARD C, MARTY M, LANE D, CALVO F AND SOUSSI T. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52, 6380-6384.
32. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53, 4164-4168.
33. SOTO AM, MURAI JT, SITERI PK AND SONNENSCHEIN C. (1986). Control of cell proliferation: evidence for negative control on estrogen-sensitive T47D human breast cancer cells. Cancer Res. 46, 2271-2275.
34. SOULE D, VAZQUEZ J, LONG A, ALBERT S AND BRENNAN M. (1973). Human cell line from a pleural effusion derived from a breast carcinoma. J. Natl Cancer Inst., 51, 1409-1413.
35. STEWART N, HICKS GG, PARASKEVAS F AND MOWAT M. (1995). Evidence for a second cell cycle block at G2/M by p53. Oncogene, 10, 109-115.
36. STRASSER A, HARRIS AW, JACKS T AND CORY S. (1994). DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 72, 329-339.
37. TAKAHASHI K AND SUZUKI K. (1993). Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int. J. Cancer, 55, 453-458.
38. WHITAKER SJ, UNG YC AND MCMILLAN TJ. (1995). DNA double strand break induction and rejoining as determinants of human tumour cell radiosensitivity. A pulsed-field gel electrophoresis study. Int. J. Radiat. Biol., 67, 1, 7-18.
39. WURM R, BURNET NG, DUGGAL N, YARNOLD JR AND PEACOCK JH. (1995). Cellular radiosensitivity and DNA damage in primary human fibroblasts. Int. J. Radiat. Oncol. Biol. Phys., 30, 3, 625-633.
40. XIA F, WANG X, WANG YH, TSANG NM, YANDELL DW, KELSEY KT AND LIBER HL. (1995). Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res., 55, 12-15.